Complete pneumonia multiplex test
Reading File
Finding Sources
Finding Sources
Searching the Web
pneumonia multiplex PCR test pathogens 2025 clinical use
Reading File
Reading File
Finding Sources
Reading File
Reading File
Here is a complete overview of the Pneumonia Multiplex Test based on authoritative textbook sources and current literature:
Pneumonia Multiplex Test - Complete Overview
What Is It?
A pneumonia multiplex test uses nucleic acid amplification (typically PCR) to detect multiple respiratory pathogens simultaneously from a single clinical specimen. The landmark platform is the BioFire FilmArray Pneumonia Panel (BioFire Diagnostics), which is FDA-cleared and uses a sample-to-answer format.
Specimen Types
The BioFire FilmArray Pneumonia Panel is approved for lower respiratory tract (LRT) specimens:
- Expectorated or induced sputum
- Tracheal aspirates
- Bronchoalveolar lavage (BAL) fluid
Most other respiratory multiplex panels (e.g., extended respiratory viral panels) are cleared only for upper respiratory tract samples (nasopharyngeal swabs/aspirates). It is important to confirm with the local laboratory that LRT specimens have been validated on their platform before sending.
Targets Detected
Viruses (qualitative)
| Pathogen |
|---|
| Influenza A |
| Influenza B |
| RSV (Respiratory Syncytial Virus) |
| Human Metapneumovirus |
| Parainfluenza Virus |
| Adenovirus |
| Coronaviruses (including SARS-CoV-2) |
| Rhinovirus / Enterovirus |
Bacteria - Semiquantitative (15 targets)
| Typical/Pyogenic | Atypical |
|---|---|
| Streptococcus pneumoniae | Mycoplasma pneumoniae |
| Haemophilus influenzae | Chlamydophila (Chlamydia) pneumoniae |
| Staphylococcus aureus | Legionella pneumophila |
| Klebsiella pneumoniae | |
| Pseudomonas aeruginosa | |
| Acinetobacter baumannii | |
| Enterobacteriaceae | |
| Moraxella catarrhalis | |
| Bordetella pertussis/parapertussis |
Antimicrobial Resistance Genes (qualitative)
| Gene Class | Resistance Type |
|---|---|
| mecA/mecC | Methicillin resistance (MRSA) |
| KPC, NDM, OXA-48, VIM, IMP | Carbapenemases |
| CTX-M | Extended-spectrum beta-lactamases (ESBLs) |
Clinical Classification of Panels
| Panel Type | Regulatory Class | Setting | Examples |
|---|---|---|---|
| Non-waived extended panel (LRT) | CLIA non-waived (moderate/high complexity) | Accredited lab | BioFire FilmArray Pneumonia Panel |
| Non-waived extended panel (URT) | CLIA non-waived | Accredited lab | xTAG RVP FAST, GenMark eSensor |
| CLIA-waived rapid panels | Waived | Point-of-care | BioFire Respiratory Virus Panel EZ, Alere i, cobas Liat (Roche), Xpert Xpress (Cepheid) |
Diagnostic Performance
From the FDA approval prospective study (BioFire FilmArray Pneumonia Panel):
- Positive Percent Agreement (PPA): 75-100% depending on target
- Negative Percent Agreement (NPA): 89-100% depending on target
For individual pathogens of note:
- Mycoplasma pneumoniae PCR: pooled sensitivity ~83%; now available via multiplex panel where standalone PCR was previously limited (Quick Compendium of Clinical Pathology)
- Legionella pneumophila PCR: pooled sensitivity 83% (95% CI: 79-87%), specificity 90% (95% CI: 88-92%) in meta-analysis of 9 studies - Henry's Clinical Diagnosis
- Rapid influenza NATs (CLIA-waived): pooled sensitivity 92% (influenza A), 95% (influenza B); specificity >99% - Murray & Nadel's Respiratory Medicine
Detection rates for CAP pathogens improve from ~23-46% with traditional methods to 41-68% with multiplex PCR-based tests.
Key Pathogens and Their Traditional vs. Multiplex Diagnosis
| Organism | Traditional Method | Multiplex Advantage |
|---|---|---|
| Legionella pneumophila | Urine antigen (serogroup 1 only), BCYE culture (2-5 days), silver stain | PCR detects all serogroups; FDA-approved multiplex panel |
| Mycoplasma pneumoniae | Serology (EIA), cold agglutinins | PCR now available in commercial multiplex panel |
| C. pneumoniae | Serology | PCR in multiplex; culture not practical |
| Influenza A/B | Rapid antigen (low sensitivity) | Multiplex NAT: sensitivity >92% |
| MRSA | Culture + sensitivity | mecA gene detected directly |
| Carbapenem-resistant organisms | Culture + MIC testing | KPC, NDM, VIM, IMP genes detected directly |
Clinical Indications
The multiplex pneumonia panel is particularly useful in:
- Community-acquired pneumonia (CAP) - especially moderate-severe cases
- Hospital-acquired/ventilator-associated pneumonia (HAP/VAP) - where resistance gene detection guides de-escalation
- Immunocompromised patients - shortens time-to-result; effective at ruling out multi-drug resistant organisms, reducing broad-spectrum antibiotic exposure
- ICU patients - BAL-based testing improves yield over NPS
- When atypical pathogens are suspected (elderly, cold agglutinins, exposure history)
Antimicrobial Stewardship Impact
- Reduces time from sample to result (typically ~1 hour for BioFire FilmArray vs. 24-72 hours for culture)
- Resistance gene detection allows earlier de-escalation from broad-spectrum antibiotics
- Season-specific multiplex PCR strategies significantly expedite pathogen detection and improve certain aspects of antimicrobial stewardship
- In immunocompromised patients, mPCR could reduce exposure to broad-spectrum antibiotics (2025 ICU study)
Important Limitations
- Colonization vs. infection - a positive result does not always confirm active infection (especially for bacteria that can colonize the airway)
- Semiquantitative reporting - bacterial targets are reported with copy numbers to help distinguish colonization from infection; clinical correlation required
- Cannot fully replace culture - susceptibility testing still requires culture for minimum inhibitory concentration (MIC) data
- Coverage gaps - rare pathogens (e.g., Pneumocystis jirovecii, endemic fungi, Nocardia) are not included on standard panels
- CLIA classification - most LRT panels require accredited laboratory setup; not all can be run at the bedside
Sources:
- Murray & Nadel's Textbook of Respiratory Medicine (2-Volume), Chapter 19
- Henry's Clinical Diagnosis and Management by Laboratory Methods - Chapter 57 (Legionella)
- Quick Compendium of Clinical Pathology, 5th ed. - Sections 1553.10, 3.5.13
- Tietz Textbook of Laboratory Medicine, 7th ed.
- 2025 multicenter fast multiplex PCR evaluation (Wang et al., Frontiers 2025)
- Multiplex pneumonia panel for ED patients, 2025 (Tsui et al., Microbiology Spectrum 2025)
- mPCR in immunocompromised ICU patients, 2025 (PMC 2025)
This is a shared conversation. Sign in to Orris to start your own chat.